Malaysia gives conditional approval for use of Ronapreve COVID-19 treatment
Reuters
December 14, 2021 11:01 MYT
December 14, 2021 11:01 MYT
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. - REUTERS/Brendan McDermid
KUALA LUMPUR: Malaysia's health ministry said on Tuesday it has given conditional approval for the use of the single-dose antibody cocktail Ronapreve, developed by Regeneron and Roche, to treat COVID-19.
It has also approved a request from Merck & Co for a clinical trial import license for its COVID-19 pill Molnupiravir, to be used as part of studies being conducted in Malaysia, the ministry said in a statement.